Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction

Study ID	NCT00588510
Status	Recruiting
Phase	-
Source	ClinicalTrials.gov

Started	Jan 1 2000
Last Updated	Jun 19 2009
Estimated Completion	Jun 19 2009

About this clinical study

Summary

This study focusses on finding out if osteosarcoma can be detected in blood. The cells will be measured by a new laboratory technique called the polymerase chain reaction. This new technique can identify one tumor cell among one million normal cells. Using this technique Memorial Sloan-Kettering Cancer Center research doctors may be able to detect tumor cells that could not be identified any other way. This test will be in addition to cancer treatment and will not replace any other test used normally. As this technique is still unproved the results will not be given to patients or patient's doctors and will not be used to change cancer treatment.

Condition / Disease

Osteosarcoma

Therapy

Blood draw

Study Outcomes

To determine if circulating osteosarcoma cells can be reliably detected and quantitated in the blood of patients with localized and advanced osteosarcoma.
To determine the frequency circulating osteosarcoma cells can be detected in the blood of patients at diagnosis, during therapy, at the completion of all planned therapy and at relapse.
To determine if the presence of circulating osteosarcoma tumor cells is associated with patient outcome.

Overview

Gender	male, female

Target Enrollment	150

Recruiting Healthy Volunteers	No

Locations

Memorial Sloan-Kettering Cancer Center

New York

Criteria

Inclusion Criteria:

Patients with osteosarcoma are the study group.

Patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma may participate as controls.

histologically proven osteosarcoma or a history of histologically proven osteosarcoma are eligible for participation. The patient does not need to be newly diagnosed for enrollment on this protocol.

Patients with malignant diagnosis other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma are eligible to participate if they have a central venous catheter and routine blood work is being drawn.